285 results about "Hemagglutinin" patented technology

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNAs) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) than the mRNA encoding the influenza B virus, and methods of eliciting an immune response by administering said compositions. In particular, the disclosures relate to mRNA encoding these antigens formulated in a lipid nanoparticle (LNP).

The present disclosure relates to compositions and methods for vaccinating a subject against a variety of SARS-CoV-2 variants and other respiratory viruses, the compositions and methods involve preparing and delivering extracellular vesicles expressing on its surface an engineered spike protein, an engineered nucleocapsid protein, an engineered hemagglutinin protein, and / or an engineered respiratory syncytial virus pre-fusion or fusion (RSV F) protein. The invention also relates to compositions and methods for designing, preparing, making, formulating and / or using spike display, nucleocapsid display, hemagglutinin display and / or RSV F display vesicle vaccines, the spike display, nucleocapsid display, hemagglutinin display, and / or RSV F display vesicle vaccines are designed to elicit potent humoral and cellular immune responses against a variety of respiratory viruses and variants.

Provided herein are immunogenic compositions comprising a chimeric influenza A virus HA and a CpG oligonucleotide adjuvant. Also provided herein are immunogenic compositions comprising an inactivated influenza A virus described herein or inactivated split influenza A virus described herein and a CpG oligonucleotide adjuvant described herein, wherein the inactivated influenza A virus or inactivated split influenza A virus comprises a chimeric hemagglutinin described herein. The immunogenic compositions may be used in a sequential immunization regimen. Also provided herein are methods of immunizing a subject against influenza virus disease (e.g., influenza virus disease caused by influenza A virus, such as, e.g., group 2 influenza A virus) using an immunogenic composition described herein. Further, provided herein are methods of preventing influenza virus disease (e.g., influenza virus disease caused by influenza A virus, such as, e.g., group 2 influenza A virus) in a subject using an immunogenic composition described herein.

Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

To disclose modified influenza virus neuraminidases that improve viral replication, thus improving the yield of vaccine viruses.SOLUTION: Expression of such modified neuraminidases by influenza virus stabilizes co-expressed hemagglutinins, ensuring that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.SELECTED DRAWING: None

The invention discloses an influenza A virus neutralizing antibody and application thereof, the neutralizing antibody comprises a heavy chain and a light chain, the heavy chain comprises a heavy chain CDR1 with an amino acid sequence as shown in SEQ ID NO: 5, a heavy chain CDR2 with an amino acid sequence as shown in SEQ ID NO: 6 and a heavy chain CDR3 with an amino acid sequence as shown in SEQ ID NO: 7; the light chain comprises a light chain CDR1 with an amino acid sequence as shown in SEQ ID NO: 8, a light chain CDR2 with an amino acid sequence as shown in SEQ ID NO: 9 and a light chain CDR3 with an amino acid sequence as shown in SEQ ID NO: 10. The antibody disclosed by the invention has high-efficiency broad-spectrum neutralizing activity in influenza A virus, and can be combined with various subtypes of hemagglutinin and inhibit splitting of hemagglutinin precursor protein and conformational change of the hemagglutinin in an acid environment. The invention has important significance and application prospect for preventing and treating diseases caused by influenza A virus.

The invention discloses a kit, an antibody and a method for detecting A-type botulinum toxin hemagglutinin-70. The kit of the present invention comprises an antibody capable of targeting type A botulinum toxin hemagglutinin-70. The antibody disclosed by the invention has good affinity and stability, can be widely applied to detection of A-type botulinum toxin hemagglutinin-70, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detecting botulinum toxin component antibodies, and provides a quality control means for commercialized and self-researched antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.

Provided is an isolated mRNA molecule, which contains a nucleotide sequence encoding a chimeric immunogenic polypeptide, wherein the chimeric immunogenic polypeptide contains an immunogenic fragment of hemagglutinin (HA) of influenza A H5N1, an immunogenic fragment of hemagglutinin (HA) of influenza A H1N1, and an immunogenic fragment of hemagglutinin (HA) of influenza B Victoria, which are linked to each other. Further provided are a composition and vaccine containing the mRNA, a fusion protein encoded thereby, and a method using same for inducing an immune response to influenza virus in a subject.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

In one aspect, provided herein is a mosaic influenza virus hemagglutinin (HA) polypeptide comprising an influenza A virus HA ectodomain of an influenza A virus strain HA, wherein the HA ectodomain comprises an HA stem domain of the influenza A virus strain HA and an HA globular head domain of the influenza A virus strain HA, wherein the HA globular head domain of the influenza A virus strain HA has been engineered to comprise one or more amino acid substitutions in one, two, three, four or all of the antigenic sites. In another aspect, provided herein are immunogenic compositions comprising such a mosaic influenza virus HA polypeptide or an influenza A virus comprising such a mosaic influenza virus HA polypeptide. In yet another aspect, provided herein are methods for immunizing a subject against an influenza A virus in a subject comprising administering such an immunogenic composition to the subject.

The invention belongs to the technical field of biology, and relates to an anti-H6 subtype avian influenza virus hemagglutinin protein monoclonal antibody 1H1 and application thereof, cell engineering and antibody engineering technologies are utilized to obtain a hybridoma cell line for secreting a hemagglutinin monoclonal antibody, ascites is induced by mice of the same strain to prepare the anti-hemagglutinin protein monoclonal antibody 1H1, the anti-hemagglutinin protein monoclonal antibody 1H1 is identified as an IgG1, kappa type, and the anti-hemagglutinin protein monoclonal antibody 1H1 is identified as an anti-H6 subtype avian influenza virus hemagglutinin protein monoclonal antibody. And the application of the antibody is realized through technologies of affinity purification, immunization and the like. The monoclonal antibody has the advantages that the preparation method is simple and easy to implement, more importantly, the monoclonal antibody prepared by the method can have multiple purposes, an effective tool is provided for auxiliary diagnosis of H6 subtype avian influenza virus infection in a clinical sample, and the monoclonal antibody can be popularized and applied to multiple detection technologies and clinical and experimental research.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.

Provided herein are immunogenic compositions comprising a mosaic influenza B virus hemagglutinin (HA) and a CpG oligonucleotide adjuvant. Also provided herein are immunogenic compositions comprising an inactivated influenza B virus described herein or inactivated split influenza B virus described herein and a CpG oligonucleotide adjuvant described herein, wherein the inactivated influenza B virus or inactivated split influenza B virus comprises a mosaic HA described herein. The immunogenic compositions may be used in a sequential immunization regimen. Also provided herein are methods of immunizing a subject against influenza virus disease (e.g., influenza virus disease caused by influenza B virus) using an immunogenic composition described herein. Further, provided herein are methods of preventing influenza virus disease (e.g., influenza virus disease caused by influenza B virus) in a subject using an immunogenic composition described herein.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is comprised between 1.5:1 and 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and / or Influenza B.

The invention discloses a method for purifying pilin Fim < 2 > / 3 without pertussis component antigen residue. Specifically, pertussis thalli are subjected to heat extraction treatment and then subjected to salting-out, anion exchange and cation exchange to obtain a crude product, and the high-purity pertussis pilin Fim2 / 3 without residues such as pertussis toxin PT, pertussis filamentous hemagglutinin FHA and pertussis adhesin PRN is obtained after multi-mode anion composite chromatography. The pertussis mycoprotein Fim < 2 > / 3 prepared by the method has high biological safety due to high purity, for a component pertussis vaccine taking the pertussis mycoprotein Fim < 2 > / 3 as a new component, a detoxification process which must be adopted due to residues of pertussis toxin PT and the like is avoided, the production process of the component pertussis vaccine is reduced, and the production cost is reduced. The utilization rate of the pertussis pilin Fim2 / 3 and the production and preparation efficiency of the component pertussis vaccine are improved.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

Provided herein are group 2 influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and / or treatment of influenza virus infections.

This application relates to modified H5 influenza hemagglutinin polypeptides and messenger ribonucleic acids (mRNAs) encoding the same, as well as compositions and vaccines comprising the same and methods of using the same, such as in the prevention and / or treatment of diseases or conditions caused by influenza A viruses, particularly influenza A virus, subtype H5, such as H5N8 or H5N1.

The invention belongs to the technical field of biological medicines, and particularly relates to a dissociation liquid applied to an aluminum adjuvant adsorption influenza vaccine and a method for measuring the antigen content. The dissociation liquid disclosed by the invention is prepared from a potassium phosphate salt solution, diethanol amine, TritonX-100, tween-20, dodecyl dimethyl betaine and water. The dissociation liquid is excellent in dissociation efficiency, the dissociation recovery rate of the dissociation liquid to H1N1, H3N2 and BV type influenza vaccine hemagglutinin reaches 106%-110%, the antigen activity can be effectively protected, operation is easy and convenient, adaptability is wide, a dissociated sample can be directly used for mainstream detection methods such as a one-way immunodiffusion test, an enzyme-linked immunosorbent assay and a high performance liquid chromatography method, and the dissociation liquid has good application prospects. The precise quantification of the antigen content in the aluminum adjuvant adsorption influenza vaccine is realized, and a reliable technical support is provided for vaccine quality control.

The invention provides a preparation method of an H5 and H7 subtype recombinant avian influenza virus hemagglutination inhibition test antigen, which overcomes the defects that in the existing avian influenza virus antibody hemagglutination inhibition test, a standard substance cannot accurately detect the virulence of a strain to be detected and cannot truly reflect the immune effect of an avian influenza vaccine, and the H5 and H7 subtype recombinant avian influenza virus hemagglutination inhibition test antigen can be obtained by adjusting inactivation and purification processes. The pH value is adjusted, so that impure protein is separated out more easily, components influencing a detection result are reduced, the binding capacity of hemagglutinin is changed, the activity of the hemagglutinin is more easily bound with a serum antibody, the impure protein, inorganic salt and urate in an antigen are removed, and errors in the detection process are reduced. The method provided by the invention is high in specificity, the detection result is more accurate and reliable, and the effectiveness of the vaccine can be better evaluated.

Immunogenic compositions comprising hemagglutinin (HA) variants and / or neuraminidasc (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.

This invention relates to retroviral gene transfer vectors, particularly lentiviral vectors, pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).

The present invention relates to the production of modified influenza vial proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

To provide a method for stably and efficiently producing a protein in secretory production of a target protein using BEVS.SOLUTION: The present invention also provides a method for producing a fusion protein, comprising the steps of expressing the fusion protein in cultured insect cells using a recombinant baculovirus comprising a polynucleotide encoding the fusion protein, and recovering the fusion protein from the culture supernatant, wherein the fusion protein is derived from silkworm H1N1 influenza virus hemagglutinin or silkworm osteonectin.SELECTED DRAWING: None